Preemptive treatment of minimal residual post transplant in CML using real-time quantitative RT-PCR: A prospective, randomized trial

Bone Marrow Transplantation

Volumn 33, Issue 5, 2004, Pages 535-542

  Kim, Y J ^a   Kim, D W ^a,b   Lee, S ^a   Chung, N G ^a   Hwang, J Y ^a   Kim, Y L ^a   Min, C K ^a   Kim, C C ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Chronic myelogenous leukemia; Hematopoietic stem cell transplantation; Immunotherapy; Minimal residual disease; Real time quantitative PCR; Relapse

Indexed keywords

CD3 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMATINIB; INTERFERON; METHOTREXATE; TACROLIMUS;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; LUNG MYCOSIS; MALE; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; PANCYTOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PIPERAZINES; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 1842537907     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704386     Document Type: Article

References (28)

1. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319: 990-998.
2. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
3. Gratwohl A, Hermans J, Niederwieser D et al. Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993; 12: 509-516.
4. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: A report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17: S5-S6.
5. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
6. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587-599.
7. Amabile M, Giannini B, Testoni N et al. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica 2001; 86: 252-259.
8. Emig M, Saussele S, Wittor H et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
9. Lee YK, Lee DW, Kim YL et al. Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: The feasibility of iFISH monitoring of therapeutic response in peripheral blood. Int J Hematol 2002; 76: 180-185.
10. Kim YJ, Kim DW, Lee S et al. Comprehensive comparison of FISH, RT-PCR, and Q-RT-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol 2002; 68: 272-280.
11. Preudhomme C, Revillion F, Merlat A et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999; 13: 957-964.
12. Eder M, Battmer K, Kafert S et al. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999; 13: 1383-1389.
13. van Rhee F, Savage D, Blackwell J et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055-1061.
14. Collins Jr RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 4334-4344.
15. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
16. Formankova R, Honzatkova L, Moravcova J et al. Prediction and reversion of post-transplant relapse in patients with chronic myeloid leukemia using mixed chimerism and residual disease detection and adoptive immunotherapy. Leuk Res 2000: 24: 339-347.
17. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
18. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 seattle patients. Am J Med 1980, 204-217.
19. Hook EB. Exclusion of chromosomal mosaicism: Tables of 90%, 95% and 99% confidence limits and comments on use. Am J Hum Genet 1977; 29: 94-97.
20. Cross NCP. Assessing residual leukaemia. Baillières Clin Haematol 1997; 10: 389-403.
21. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
22. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
23. Wassmann B, Klein SA, Scheuring U et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 721-724.
24. Olavarria E, Craddock C, Dazzi F et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861-3862.
25. Kantarjian HM, O'Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590-1595.
26. McCann SR. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML. Blood 2003; 101: 1200-1201.
27. Kernan NA, Collins NH, Juliano L et al. T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68: 770-773.
28. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.